Skip to main content
On Our Radar

Synuclein Antibodies Not a Reliable Biomarker for Parkinson’s

Synuclein Antibodies Not a Reliable Biomarker for Parkinson’s

Previous research has examined whether levels of alpha-synuclein autoantibodies (α-syn AAb) differ between patients with Parkinson’s disease and healthy controls to determine its utility as a biomarker, however, results have been inconclusive.

In a new paper published in Molecular and Cellular Neuroscience, researchers looked at α-syn Aab levels in the largest study sample to date—one that included 157 patients with Parkinson’s disease from two independent cohorts, 46 age- and sex-matched healthy controls, and 92 patients with other neurodegenerative disorders, including Alzheimer’s disease, progressive supranuclear palsy, and spinocerebellar ataxia.

Patients with Parkinson’s disease had significantly lower α-syn Aab levels than healthy controls, however, the same was true for patients with other neurological disorders. In addition, α-syn AAb levels significantly differed between the two cohorts of patients with Parkinson’s (cohort 1: 34.13 ± 29.28 μg/mL; cohort 2: 20.18 ± 14.85 μg/mL).

The study authors conclude that serum α-syn AAb levels are not a reliable biomarker for Parkinson’s because of their inability to differentiate between patients with Parkinson’s and patients with other neurodegenerative disorders. Further α-syn AAbs levels showed high variability in all the groups tested, such that they aren’t reliable in distinguishing healthy controls from those with Parkinson’s or other neurodegenerative diseases.

Read the study highlights

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.